Breaking News

Financial Report: Biogen Idec

July 23, 2014

MS drug TECFIDERA drives growth in the quarter

Biogen Idec
 
2Q Revenues: $2.4 billion (+40%)

2Q Earnings: $723.1 million (+47%)

YTD Revenues: $4.6 billion (+45%)

YTD Earnings: $1.2 billion (+31%)

Comments: Growth in the quarter was driven by continued uptake of MS drug TECFIDERA, with revenues of $700 million, consisting of $585 million in U.S. sales and $115 million in sales outside the U.S. TYSABRI revenues were $533 million, up 38%. Avonex revenues were flat at $774 million in the quarter. Net revenues relating to RITUXAN and GAZYVA from the company’s unconsolidated joint business arrangement with Roche's Genentech, were $303 million, up from $289 million in 2Q13.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks